Results 1 to 10 of about 13,766 (257)

FDA-Approved Antibacterials and Echinocandins [PDF]

Antibiotics
Since 1955, a total of 12 peptide-based drugs with antimicrobial or antifungal properties have received approval from the Food and Drug Administration (FDA).
Othman Al Musaimi
doaj   +5 more sources

Evolutionary accumulation of FKS1 mutations from clinical echinocandin-resistant Candida auris [PDF]

Emerging Microbes and Infections
Introduction: Drug resistance to echinocandins, first-line drugs used to treat Candida auris infection, is rapidly emerging. However, the accumulation of mutations in genes other than FKS1 (before an isolate develops to resistance via FKS1 mutations ...
Sufei Tian, Yusheng Wu, Hailong Li, Chen Rong, Na Wu, Yunzhuo Chu, Ning Jiang, Jingping Zhang, Hong Shang   +8 more
doaj   +2 more sources

Multifactorial Role of Mitochondria in Echinocandin Tolerance Revealed by Transcriptome Analysis of Drug-Tolerant Cells

mBio, 2021
Fungal infections cause significant mortality and morbidity worldwide, and the limited existing antifungal reservoir is further weakened by the emergence of strains resistant to echinocandins, a first line of antifungal therapy.
Rocio Garcia-Rubio, Cristina Jimenez-Ortigosa, Lucius DeGregorio, Christopher Quinteros, Erika Shor, David S. Perlin   +5 more
doaj   +1 more source

Curcumin Epigenetically Represses Histone Acetylation of Echinocandin B Producing Emericella rugulosa

Physiologia, 2023
Echinocandin B is a natural product that possesses potent antifungal property against a wide array of fungi. This antifungal agent is produced by Emericella rugulosa. The biosynthetic genes of echinocandin B are physically organized in two gene clusters (
Vandana Kumari, Vinay Kumar, Manisha Kaushal, Antresh Kumar   +3 more
doaj   +1 more source

Hsp90 governs dispersion and drug resistance of fungal biofilms [PDF]

, 2011
Fungal biofilms are a major cause of human mortality and are recalcitrant to most treatments due to intrinsic drug resistance. These complex communities of multiple cell types form on indwelling medical devices and their eradication often requires ...
A Lupetti, A Viudes, C d'Enfert, CA Kumamoto, CJ Nobile, CJ Nobile, D Andes, D Shahinas, David Andes, E Mowat, EM Kojic, ET Burt, G Ramage, G Ramage, G Ramage, G Ramage, G Ramage, Gordon Ramage, J McCourtie, J Nett, J Trepel, JB Anderson, JC Young, JE Nett, Jeniel Nett, Jose L. Lopez-Ribot, JR Blankenship, JS Finkel, L Ostrosky-Zeichner, LE Cowen, LE Cowen, LE Cowen, LE Cowen, LE Cowen, Leah E. Cowen, LH Pearl, LS Wilson, M Taipale, MA Pfaller, MA Pfaller, MJ Seidler, ML Richard, MM McNeil, Nicole Robbins, P Perumal, P Uppuluri, P Uppuluri, P Uppuluri, P Uppuluri, P Uppuluri, PK Mukherjee, Priya Uppuluri, R Pallavi, Ranjith Rajendran, Robin Charles May, RS Shapiro, RS Shapiro, S Garcia-Sanchez, S Park, S Perea, SD Singh, SJ Lin, SL LaFayette, SM Noble, SV Balashov, SZ Usmani, TE Zaoutis, Y Kaneko, YS Kim, Z Odabasi   +69 more
core   +13 more sources

Whole genome analysis of echinocandin non-susceptible Candida Glabrata clinical isolates: a multi-center study in China

BMC Microbiology, 2023
Background Candida glabrata is an important cause of invasive candidiasis. Echinocandins are the first-line treatment of invasive candidiasis caused by C. glabrata.
Yi Li, Xin Hou, Ruoyu Li, Kang Liao, Ling Ma, Xiaoming Wang, Ping Ji, Haishen Kong, Yun Xia, Hui Ding, Wei Kang, Ge Zhang, Jin Li, Meng Xiao, Yingxing Li, Yingchun Xu   +15 more
doaj   +1 more source

Loss of Septation Initiation Network (SIN) kinases blocks tissue invasion and unlocks echinocandin cidal activity against Aspergillus fumigatus.

PLoS Pathogens, 2021
Although considered effective treatment for many yeast fungi, the therapeutic efficacy of the echinocandin class of antifungals for invasive aspergillosis (IA) is limited.
Ana Camila Oliveira Souza, Adela Martin-Vicente, Ashley V Nywening, Wenbo Ge, David J Lowes, Brian M Peters, Jarrod R Fortwendel   +6 more
doaj   +1 more source

Global analysis of the evolution and mechanism of echinocandin resistance in Candida glabrata. [PDF]

PLoS Pathogens, 2012
The evolution of drug resistance has a profound impact on human health. Candida glabrata is a leading human fungal pathogen that can rapidly evolve resistance to echinocandins, which target cell wall biosynthesis and are front-line therapeutics for ...
Sheena D Singh-Babak, Tomas Babak, Stephanie Diezmann, Jessica A Hill, Jinglin Lucy Xie, Ying-Lien Chen, Susan M Poutanen, Robert P Rennie, Joseph Heitman, Leah E Cowen   +9 more
doaj   +1 more source

Evaluation of an Antifungal Stewardship Initiative Targeting Micafungin at an Academic Medical Center

Antibiotics, 2023
Delays in the treatment of proven invasive fungal disease have been shown to be harmful. However, empiric treatment for all patients at risk of infection has not demonstrated benefit.
J. Myles Keck, David A. Cretella, Kayla R. Stover, Jamie L. Wagner, Katie E. Barber, Tulip A. Jhaveri, Prakhar Vijayvargiya, Zerelda Esquer Garrigos, Mary Joyce B. Wingler   +8 more
doaj   +1 more source

An Alanine Aminotransferase Is Required for Biofilm-Specific Resistance of Aspergillus fumigatus to Echinocandin Treatment

mBio, 2022
Alanine metabolism has been suggested as an adaptation strategy to oxygen limitation in organisms ranging from plants to mammals. Within the pulmonary infection microenvironment, Aspergillus fumigatus forms biofilms with steep oxygen gradients defined by
Joshua D. Kerkaert, François Le Mauff, Benjamin R. Wucher, Sarah R. Beattie, Elisa M. Vesely, Donald C. Sheppard, Carey D. Nadell, Robert A. Cramer   +7 more
doaj   +1 more source